New Entries Could Boost Generic Drug Image In Japan - JGA President
This article was originally published in PharmAsia News
Executive Summary
Japan Generics Association President Hiroyuki Sawai said the recent generics entries of Pfizer and Daiichi Sankyo could help boost the generic drug image in Japan. Sawai said the wall between innovative and generic drug makers is disappearing and the major drug makers will establish new quality and trust for the industry. Many Japanese generics manufacturers are small to mid-sized, and generic drugs are considered in Japan to be lower in quality than brand products. JGA has implemented a series of programs to emphasize the quality and safety of generic drugs. Sawai also said that compared to the EU and the U.S., Japan still lacks systemic support to stimulate generics use, and he expects the industry will grow further as the government implements promotional measures. (Click here for more - Japanese language
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.